September 12, 2025 - 11:49

Over the past two decades, the alarming rise in substance use-related deaths among women of reproductive age has become a pressing public health concern. Recent studies indicate that overdose deaths have more than doubled in this demographic, making it a leading cause of maternal mortality across the United States. In certain states, these fatalities have reached epidemic proportions, highlighting the urgent need for effective interventions.
Buprenorphine, a medication used to treat opioid use disorder, has emerged as a promising solution. Research shows that its use not only improves health outcomes for mothers but also leads to substantial cost savings for healthcare systems. By addressing the underlying issues of addiction, buprenorphine treatment can significantly reduce the risks associated with substance use during pregnancy, ultimately benefiting both mothers and their infants.
As healthcare providers and policymakers look for effective strategies to combat this crisis, the implementation of buprenorphine treatment programs could play a crucial role in safeguarding the health of vulnerable populations.
May 9, 2026 - 22:43
College of Pharmacy & Health Sciences confers 206 degrees - NewsThe Campbell University College of Pharmacy & Health Sciences held its spring commencement ceremony to honor the achievements of the Class of 2026. A total of 206 degrees were conferred during the...
May 9, 2026 - 02:40
California Becomes First State to Offer Free Diapers for Every NewbornCalifornia is set to launch a first-of-its-kind program that will provide free diapers to every newborn in the state. The initiative, which makes California the first state in the country to offer...
May 8, 2026 - 11:45
Maryland ranked high among states for public health preparedness, but could be doing moreMaryland continues to rank among the top states in the nation for its ability to handle public health emergencies, according to a recent analysis by a national health policy organization. The state...
May 7, 2026 - 18:47
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo NordiskThe arrival of the first generic versions of semaglutide in Canada is being watched closely as a potential turning point for Novo Nordisk`s dominance in the global weight-loss and diabetes market....